Molina Healthcare, Inc. is a Fortune 500 managed care company that specializes in government-sponsored health insurance programs. Headquartered in Long Beach, California, the company provides Medicaid managed care plans, Medicare Advantage and prescription drug plans, and individual Marketplace plans under the Affordable Care Act. Through an integrated care delivery model, Molina emphasizes preventive and primary care services, care coordination, and disease management. The company serves approximately 5 million members across the United States and competes with other managed care organizations such as Centene, Elevance Health, and UnitedHealth Group. Investors closely monitor Molina for its exposure to Medicaid policy trends, medical cost ratios, and state-level contract procurement cycles. I also ran a quick comparison using Tickeron’s AI Screener to see how it stacks up against peers in the space.
Over the last 30 days, MOH shares climbed from a closing price of $201.87 on June 15, 2026, to $241.56 on July 14, 2026, representing a gain of approximately 19.7%. The upward trajectory accelerated sharply during the final week of June, when the stock jumped from roughly $201 to over $229 in just two trading sessions. The stock also hit a new 52-week high of $243.77 on July 13, 2026. Over the broader quarter, the rally has been even more pronounced. From mid-April levels around $170–$180, Molina shares have advanced more than 35%, pushing the 50-day simple moving average to approximately $200 and the 200-day moving average to roughly $174. The stock's year-to-date gain has approached 40%, reflecting a sustained rebound from the $121.06 low reached during the trailing twelve-month period.
Several catalysts converged to power Molina's approximately 19.7% advance. The most impactful event was the June 10 announcement that the Illinois Department of Healthcare and Family Services intends to award a Medicaid Managed Care contract to Molina's Illinois subsidiary. The HealthChoice Illinois contract, covering approximately 3.1 million Medicaid beneficiaries, carries an initial four-and-a-half-year term with an option for an additional five-and-a-half years and is set to begin January 1, 2027. Shortly afterward, RBC Capital initiated coverage on Molina with a Sector Perform rating and a $216 price target, highlighting a path to $25 in adjusted EPS by 2029. In late June, Weiss Ratings upgraded Molina from a "sell" to a "hold" rating. The stock also benefited from an index reclassification: Molina was removed from several Russell growth and defensive indices and added to the Russell 2500 Index and Russell 2500 Value Benchmark, which drove incremental passive and value-oriented fund flows. Further supporting sentiment, TD Cowen raised its price target to $230 from $163, Truist Financial lifted its target to $250 from $205, and Sanford C. Bernstein maintained an Outperform rating with a $286 price target. Wells Fargo also raised its target to $235 from $159.
The broader quarterly rally was anchored by Molina's Q1 2026 earnings report on April 22, where adjusted EPS of $2.35 handily beat the consensus estimate of $1.57. Although premium revenue of $10.2 billion came in slightly below expectations and reflected a 3.1% year-over-year decline, the earnings beat and management's reaffirmation of full-year guidance at approximately $42 billion in premium revenue and at least $5.00 in adjusted EPS provided a stabilizing catalyst. The company's May 8 investor day reinforced confidence with a multi-year roadmap targeting $25 in adjusted EPS by 2029, driven by organic growth, new contract wins, and margin restoration. Institutional accumulation was another powerful tailwind: Madison Avenue Partners LP disclosed a new $110 million position, the State of Michigan Retirement System increased its stake by 1,568%, and AQR Capital Management boosted its holdings by 217%. The planned exit from the Medicare Advantage-Part D product and a strategic shift toward dual-eligible integrated care products further reshaped the investment narrative toward long-term margin recovery.
For traders seeking data-driven approaches to stocks like MOH, Tickeron’s Trending AI Robots page offers a curated selection of top-performing AI trading bots. While Tickeron hosts hundreds of AI-driven trading bots that collectively trade thousands of tickers across global markets, only the most relevant and consistently high-performing strategies appear in the Trending section. These bots span a variety of methodologies, including trend-following, mean-reversion, breakout, and pattern-recognition strategies, operating across different timeframes and performance benchmarks. Each bot's track record, win rate, and risk profile are transparently displayed, allowing traders to evaluate strategies before committing capital. Exploring the Trending AI Robots page can help investors identify automated strategies aligned with their trading objectives. One thing that stands out to me is how these tools can surface ideas that complement traditional fundamental analysis.
The most immediate catalyst is Molina's Q2 2026 earnings report, due after market close on July 22, 2026. Analysts project EPS of approximately $1.37 on revenue of $10.82 billion. More importantly, management has signaled it will update full-year 2026 guidance based on first-half operating results, and several analysts including TD Cowen expect the company to raise its EPS outlook above the current floor of $5.00. Key metrics to monitor include the consolidated medical care ratio, which analysts expect at 92.4% for Q2, and Medicaid membership trends following the expected 6% membership decline for 2026. Longer term, the Illinois Medicaid contract implementation, the transition toward dual-eligible integrated care products, and the trajectory of Medicaid rate adequacy as states face budget pressures tied to OBBBA provisions in 2028 remain critical variables. With the stock trading near consensus analyst price targets, the upcoming earnings call will likely set the tone for the next leg of MOH's trajectory.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Moving Average Convergence Divergence (MACD) for MOH turned positive on June 25, 2026. Looking at past instances where MOH's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 25, 2026. You may want to consider a long position or call options on MOH as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MOH advanced for three days, in of 323 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 227 cases where MOH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MOH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MOH broke above its upper Bollinger Band on June 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. MOH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.085) is normal, around the industry mean (5.188). P/E Ratio (64.761) is within average values for comparable stocks, (51.544). MOH's Projected Growth (PEG Ratio) (2.305) is slightly higher than the industry average of (1.453). MOH's Dividend Yield (0.000) is considerably lower than the industry average of (0.018). P/S Ratio (0.278) is also within normal values, averaging (0.707).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MOH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of health care services to persons eligible for Medicaid
Industry ManagedHealthCare